Anzeige
Mehr »
Login
Montag, 27.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
2.059 Leser
Artikel bewerten:
(2)

CoinShares International Limited Introduces Two Zero Management Fee Index ETPs (CoinShares Physical Top 10 Crypto Market ETP & CoinShares Physical Smart Contract Platform ETP), Enhancing Crypto Accessibility for Investors

Finanznachrichten News

New zero management fee ETPs provide seamless experience for investors looking to access large cap digital assets and smart contract platforms.

March 27, 2023 | SAINT HELIER, Jersey - CoinShares ("the Company") (Nasdaq First North Growth Market: CS; US OTCQX: CNSRF), Europe's largest digital asset investment firm with US$2.2bn* in AUM, today announced the addition of two physically-backed Index ETPs to their growing range of crypto ETPs listed on Germany's main market Xetra.

The Issuer formally announced on March 27, 2023 a reduction in the management fees to 0.0% p.a. for both the CoinShares Physical Top 10 Crypto Market ETP (Ticker: CTEN) and CoinShares Physical Smart Contract Platform ETP (Ticker: CSSC). Both products track bespoke indices developed in partnership with Compass Financial Technologies.

CoinShares Physical Top 10 Crypto Market ETP
Management Fee: Reduced to 0.0% p.a.
ISIN: JE00BPRDNL86
Ticker: CTEN
WKN: A3G4FD
Rebalance schedule: Quarterly
Weighting methodology: Market Capitalization subject to a maximum 35% weight for each constituent

Cost-efficient, transparent exposure to the large cap crypto market via a regulated product. Investors can diversify across the largest crypto projects.

CoinShares Physical Smart Contract Platform ETP
Management Fee: Reduced to 0.0% p.a.
ISIN: JE00BPRDNM93
Ticker: CSSC
WKN: A3G4FE
Rebalance schedule: Quarterly
Weighting methodology: Market Capitalization subject to a maximum 35% weight for each constituent

Cost-efficient, transparent exposure to the infrastructure layer of the digital asset market via a regulated product. Investors can therefore gain exposure to the universe of future dApps, DeFi, NFT and Web3 protocols without having to select them individually.

Frank Spiteri, CoinShares' Head of Asset Management, commented on the news, "We are excited to unveil our two innovative new Index ETPs to the market today, both of which have had their management fees reduced to 0.0% p.a.. With CTEN, investors can gain wider market exposure with reduced concentration risk compared to single coins, whilst CSSC offers investors passive exposure to the Web3 revolution in a single diversified, regulated, transparent product."

CTEN and CSSC were developed to meet demand in the market for Index ETPs that accurately capture trends in the digital asset universe and maximise risk-adjusted performance in the most cost-efficient manner possible.

CoinShares reports that equally-weighted indices usually require a larger number of constituents to outperform their market-cap weighted counterparts, which directly conflicts with the eligible coin restraints imposed by most major European exchanges, and which can lead to higher portfolio turnover costs.

The 35% maximum weight seeks at reducing the concentration risk of the indices, which the firm believes is particularly relevant in a market still so heavily dominated by one asset: Bitcoin.

The quarterly rebalancing schedule and a maximum number of ten constituents allows the products to stay up-to-date with changes in the cryptocurrency market without suffering from the high trading costs associated with more frequent rebalancing strategies.

Guillaume Le Fur, Founding Partner, CEO at Compass Financial Technologies, added, "We are delighted to be extending our partnership with CoinShares with the development and launch of these two new crypto indices. These indices are a reflection of Compass's continued commitment to innovation in the digital assets industry and we look forward to further collaboration with the CoinShares team in the future."

*As of March 23, 2022

About the CoinShares Group
CoinShares is the European digital asset manager that delivers a broad range of financial services across investment management, trading and securities to a wide array of clients that includes corporations, financial institutions and individuals. Founded in 2013, the firm is headquartered in Jersey, with offices in France, Stockholm, the UK and the US. CoinShares is regulated in Jersey by the Jersey Financial Services Commission, in France by the Autorité des marchés financiers, in the US by the Financial Industry Regulatory Authority. CoinShares is publicly listed on the Nasdaq Stockholm under the ticker CS and the OTCQX under the ticker CNSRF.

For more information on CoinShares, please visit: https://coinshares.com
Company | +44 (0)1534 513 100 | enquiries@coinshares.com
Investor Relations | +44 (0)1534 513 100 | enquiries@coinshares.com

PRESS CONTACT

CoinShares
Benoît Pellevoizin
bpellevoizin@coinshares.com

M Group Strategic Communications
Peter Padovano
coinshares@mgroupsc.com



© 2023 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.